Kei Kishimoto

Company: Selecta Biosciences

Job title: Chief Scientific Officer

Seminars:

Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles with leads to massive expansion of antigen-specific Tregs 2:00 pm

Engineered IL-2 molecules selective for the high affinity IL-2 receptor expressedon Tregs have been shown to non-selectively expand Tregs in vivo and are being developed for the treatment of autoimmune diseases We have developed tolerogenic nanoparticles that have been shown to induce antigen-specific immune tolerance and are in Phase 3 clinical trials in combination with…Read more

day: Day One